Foundation Medicine, OneOncology partner to bring precision oncology to community practices

NEW YORK – Foundation Medicine and OneOncology jointly announced on Monday a strategic partnership to use real-world clinical and genomics data to improve access to genomic profiling and personalized medicine in community oncology practices across the US. The two entities have inked a research collaboration, which will use clinico-genomic datasets […]

NEW YORK Foundation Medicine and OneOncology jointly announced on Monday a strategic partnership to use real-world clinical and genomics data to improve access to genomic profiling and personalized medicine in community oncology practices across the US.

The two entities have inked a research collaboration, which will use clinico-genomic datasets to derive molecular insights and inform patient care. “I am a big proponent of understanding the molecular landscape of a patient’s cancer in order to determine the appropriate treatment course for patients with advanced cancer over multiple lines of therapy,” Lee Schwartzberg, chief medical officer at OneOncology, said in a statement. “We’re excited to optimize comprehensive genomic profiling and its power to inform more personalized care across our network.”

Within the partnership, Nashville, Tennessee-based OneOncology, a national network of five independent, community oncology practices representing over 400 providers in the US, will use its patient data to advance research and address gaps in knowledge about cancer treatments. The partners also will work together on innovative clinical trial designs.

“The majority of patients are treated in a community setting, and through this partnership, we are excited to provide more oncologists with high-quality tools to help inform their treatment decisions,” Foundation Medicine CEO Cindy Perettie said in a statement.

Source Article

Next Post

Popular high blood pressure drug linked to increased skin cancer risk in older Australians

Thu Aug 20 , 2020
The popular high blood pressure drug, hydrochlorothiazide, has been linked to a higher risk of developing malignant melanoma and lip cancer in older Australians. Credit: Shutterstock Hydrochlorothiazide—one of the most prescribed high blood pressure drugs in Australia—has shown links to increased risks of developing skin cancer among older Australians, a […]